Proliferation- and apoptosis-related proteins in intracranial ependymomas: An immunohistochemical analysis

Journal of Neuro-Oncology

Volumn 56, Issue 1, 2002, Pages 21-28

  Verstegen, M J T ^a   Troost, D ^a   Leenstra, S ^a   Ijlst Keizers, H ^a   Bosch, D A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Bax; Bcl 2; Ependymomas; Mdm2; MIB 1; p53

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLINE; MONOCLONAL ANTIBODY KI 67; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; EPENDYMOMA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; ONCOLOGICAL PARAMETERS; PREDICTION; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TUMOR GROWTH; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; AGED; ANTIGENS, NUCLEAR; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BRAIN NEOPLASMS; CELL DIVISION; CHILD; CHILD, PRESCHOOL; EPENDYMOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; KI-67 ANTIGEN; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036206849     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014471714058     Document Type: Article

References (63)

1. Ependymoma: A follow-up study of 101 cases
2. Molecular analysis of genetic changes in ependymomas
3. Treatment of ependymomas. Clinical and non-clinical factors influencing prognosis: A review
4. Chromosomes in the genesis and progression of ependymomas
5. Cytogenetic analysis of 109 pediatric central nervous system tumors
6. Involvement of chromosome 22 in ependymomas
7. Molecular genetic analysis of chromosome arm 17p and chromosome arm 22q DNA sequences in sporadic pediatric ependymomas
8. Molecular cytogenetic studies of pediatric ependymomas
9. Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma
10. The p53 tumor-suppressor gene
11. Infrequency of p53 gene mutations in ependymomas
12. Rare occurrence of inactivating p53 gene mutations in primary non-astrocytic tumors of the central nervous system: Reappraisal by yeast functional assay
13. Mdm2 promotes the rapid degradation of p53
14. The Mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
15. Enhanced translation: A novel mechanism of Mdm2 oncogene overexpression identified in human tumor cells
16. Amplification and overexpression of Mdm2 in primary (de novo) glioblastomas
17. p53 Mutation and Mdm2 amplification in human soft tissue sarcomas
18. Amplification and overexpression of the Mdm2 gene in a subset of human malignant gliomas without p53 mutations
19. Overexpression of Mdm2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells
20. Human gliomas with wild-type p53 express Bcl-2
21. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
22. Double identity for proteins of the Bcl-2 family
23. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining
24. Regression models and life tables
25. Nonparametric estimation from incomplete observations
26. The new WHO classification of brain tumors
27. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics
28. Prognostic factors in intracranial ependymomas in children
29. Ependymomas. A clinical survey
30. Ependymal neoplasms in children
31. Ependymomas: Clinical and pathological aspects
32. The molecular biology of ependymomas
33. The prognostic significance of postoperative residual tumor in ependymoma
34. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: A report of the Children's Cancer Group
35. Lack of histopathological correlation of malignant ependymomas with postoperative survival
36. Histologic prognostic factors in ependymoma
37. Ependymoma: Internal correlations among pathological signs: The anaplastic variant
38. Point mutations and nucleotide insertions in the Mdm2 zinc finger structure of human tumours
39. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line
40. Infratentorial ependymomas in childhood; Prognostic factors and treatment
41. Cytogenetic analysis of 109 pediatric central nervous system tumors
42. Improved survival of patients with intracranial ependymomas by irradiation: Dose selection and field extension
43. Intracranial ependymoma: Long-term results of a policy of surgery and radiotherapy
44. The growth potential of ependymomas with varying grades of malignancy measured by the Ki-67 labelling index and mitotic index
45. Proliferating cell nuclear antigen expression in brain tumors, and its prognostic role in ependymomas: An immunohistochemical study
46. Ki-67 immunolabelling index is a prognostic indicator in childhood posterior fossa ependymomas
47. Ependymomas: MIB-1 proliferation index and survival
48. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms
49. Mdm2 and p53 expression in gliomas: A multivariate survival analysis including proliferation markers and epidermal growth factor receptor
50. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype
51. Apoptosis and cell proliferation in human neuroepithelial tumors
52. No evidence for functional inactivation of wild-type p53 protein by Mdm2 overexpression in gastric carcinogenesis
53. Mdm2 gene alterations and Mdm2 protein expression in breast carcinomas
54. Alternatively spliced Mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer
55. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms
56. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line
57. Bcl-2 distribution in neuroepithelial tumors: An immunohistochemical study
58. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype
59. Coexpression of genes involved in apoptosis in central nervous system neoplasms
60. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax: Bcl-2 ratio
61. Ki-67 immunoreactivity in human central nervous system tumors: A study with MIB 1 monoclonal antibody on archival material
62. Disseminated ependymomas of the central nervous system
63. Cyclin D1 and MIB-1 immunohistochemistry in ependymomas: A study of 41 cases